<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giulia</forename><surname>Marvaso</surname></persName>
							<email>giulia.marvaso@ieo.it</email>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Delia</forename><surname>Ciardo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giulia</forename><surname>Corrao</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sara</forename><surname>Gandini</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cristiana</forename><surname>Fodor</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dario</forename><surname>Zerini</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Damaris</forename><forename type="middle">Patricia</forename><surname>Rojas</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matteo</forename><surname>Augugliaro</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppina</forename><surname>Bonizzi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Pece</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Federica</forename><surname>Cattani</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ketti</forename><surname>Mazzocco</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francesco</forename><forename type="middle">Alessandro</forename><surname>Mistretta</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gennaro</forename><surname>Musi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sarah</forename><surname>Alessi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppe</forename><surname>Petralia</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gabriella</forename><surname>Pravettoni</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ottavio</forename><surname>De Cobelli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pier</forename><surname>Paolo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Di</forename><surname>Fiore</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppe</forename><surname>Viale</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberto</forename><surname>Orecchia</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><surname>Alicja Jereczek-Fossa</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Radiation Oncology</orgName>
								<orgName type="institution" key="instit1">IEO</orgName>
								<orgName type="institution" key="instit2">European Institute of Oncology IRCCS</orgName>
								<address>
									<addrLine>Via Ripamonti 435</addrLine>
									<postCode>20141</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1186/s12885-019-6117-z</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>Background: Prostate cancer (PCa) is the second most common cancer among men. New imaging-modalities have increased the diagnosed patients with limited number of metastasis after primary curative therapy, introducing so-called oligometastatic state. Stereotactic body radiotherapy (SBRT) is emerging as a low-toxicity treatment to erase PCa localizations and postpone androgen deprivation therapy (ADT). A deeper understanding of the predictive role of biomarkers is desirable for a targeted treatment selection and surveillance programs. The aims of the RADIOSA trial are: 1. Randomized clinical study (3 years for accrual and 2 years for follow-up and data analysis); 2. Imaging study, including imaging registration and METastasis Reporting and Data System (MET-RADS) criteria; 3. Pre-clinical study, development of a biobank of blood samples for the analysis of neutrophil-to-lymphocyte ratio and preparatory for a subsequent miRNA profiling. We aim to determine which arm is justified for testing in a subsequent Phase III trial. A decision-tree algorithm, based on prognosis, biological phenotype and imaging profile, will be developed.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(Continued from previous page)</head><p>Discussion: Recruiting will start in July 2019. SBRT will allow obtaining excellent PFS, local control, QoL and low toxicity. In SBRT arm, ADT deferral will allow for a drug-holiday, delaying the detrimental impact on QoL. A sufficient number of blood samples will be collected to perform biological patient profiling. A stratification tool will be established with an analysis of morphological and functional imaging, based on the use of MET-RADS criteria. So, in conclusion, RADIOSA aims to define the optimal management of bone/nodal PCa relapses in a SBRT regimen. This study will increase our knowledge on low-burden metastatic PCa in the era of high precision and high technology personalized medicine, offering highly effective therapy in terms of clinical outcome and cost-effectiveness.</p><p>Trial registration: The RADIOSA study was prospectively registered at clinicaltrials.gov (NCT03940235, May 2019).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Keywords: Prostate cancer, Radiotherapy, Oligometastasis, Androgen deprivation therapy, Stereotatic body radiation therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>PCa is the second most common cancer among men in the world (1.1 million new cases estimated) and death PCa related (estimated in over 300,000 deaths annually) correlates with metastatic state <ref type="bibr" target="#b0">[1]</ref>.</p><p>The advent of novel imaging techniques, such as Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) and Whole-Body Magnetic Resonance Imaging (WB MRI), allows an increasing an early detection and diagnosis of metastases after primary curative treatment. In clinical practice the possibility to identify a few number of lesions is called "oligometastatic state" and it is considered an intermediate phase of tumor spread with limited metastatic capacity <ref type="bibr">[2]</ref>. This state consists of low-volume disease, typically defined as the presence of up to 3-5 metastases <ref type="bibr" target="#b4">[3]</ref> treatable with a local approach (such as surgery or radiotherapy) either with or without systemic therapy.</p><p>Patients with low-volume or oligometastatic disease have improved survival compared with those with highvolume metastases or a disseminated metastatic cancer <ref type="bibr" target="#b5">[4]</ref>. While chemo-hormonal therapy is the standard of care for men with high-volume metastatic castrationsensitive PCa <ref type="bibr" target="#b6">[5]</ref>, in the low-volume metastatic PCa additional chemo-therapy did not demonstrate survival benefit <ref type="bibr" target="#b7">[6]</ref>, so SBRT is emerging as a promising low-toxicity treatment option for oligometastases both at diagnosis and recurrence <ref type="bibr" target="#b8">[7]</ref>. Small-volume high-dose SBRT limited to metastatic site might potentially eliminate all macroscopic cancer foci prolonging the progressionfree interval and postponing ADT. The aim of SBRT in this setting is to achieve local control and delay progression, and thereby postpone the need for further treatment.</p><p>Moreover, an open question in this framework is the patient QoL, to be evaluated in the balance of oligometastatic disease diagnosis, less treatment option and additional ADT-induced side effects. A deeper understanding of the predictive role of biomarkers is desirable for a targeted treatment selection and proper surveillance programs. The limitation associated with the use of the prostate-specific antigen (PSA) as diagnostic and follow-up marker stimulated significant investigations of several novel biological markers, such as blood-based parameters, microRNAs and cell-free DNA <ref type="bibr" target="#b9">[8,</ref><ref type="bibr" target="#b10">9]</ref>. However, this new approach requires a large amount of coherently collected data to give reliable and univocal results.</p><p>A further research frontier is the role of imaging in this setting of patients. Recently, the role of WB MRI has been proposed as a suitable solution for tumor detection and therapy evaluation in this setting of patients with performance at least comparable with the Choline positron emission tomography/computed tomography Ch-PET/CT <ref type="bibr" target="#b11">[10]</ref>.</p><p>Overall, clear-cut data and tools to guide a consensus about the optimal therapeutic choice for the individual clinical situation are not validated and the standard of care to recurrent PCa remains ADT, with significant side effect and deterioration of QoL <ref type="bibr" target="#b12">[11]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods/design</head><p>Aim, design, and setting of the study The present research project aims to define the optimal management of bone or nodal PCa recurrences in a SBRT regimen. As a final result, a decision-tree algorithm, based on prognosis, biological phenotype and imaging profile, will be obtained as a clinically useful tool.</p><p>This study will move forward our knowledge on lowburden metastatic PCa in the era of high-precision and high technology personalized medicine, offering highly effective therapy in terms of clinical outcome and cost effectiveness. The aim is to compare time to progression between the two study arms: SBRT only or SBRT and ADT. RADIOSA will be developed during the 5 years of the project and it is divided in two main phases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population Participant characteristics</head><p>RADIOSA is a prospective monocentric randomized phase II study in which oligorecurrent PCa patients (1-3 lesions) are randomized to two treatments and the results with the longest time to progression is selected for further study <ref type="bibr" target="#b13">[12]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eligibility criteria</head><p>The inclusion criteria are as follows:</p><p>1) Histologically proven initial diagnosis of adenocarcinoma of the prostate 2) Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/− prostate bed adjuvant/salvage radiotherapy) +/− ADT according to the European Association of Urology (EAU) guidelines 2016 <ref type="bibr" target="#b14">[13]</ref> or after any salvage therapy if biochemical progression is diagnosed in the context of castration sensitive PCa 3) Nodal relapse in the pelvis, extra-regional nodal relapse (M1a), bone metastases (M1b) on Ch-PET/ CT or WB MRI with a maximum of 3 lesions 4) Serum testosterone level &gt; 50 ng/dl at the time of randomization (castration sensitive PCa) 5) Eastern Cooperative Oncology Group (ECOG) performance status 0-1 6) Age ≥ 18 years 7) Ability to complete questionnaires about QoL 8) Written informed consent signed.</p><p>The exclusion criteria are as follows:</p><p>1) Presence of visceral metastases 2) More than three metastases 3) Inability to complete questionnaires about QoL 4) Previous invasive cancer (within 3 years before the prostate cancer diagnosis) apart from nonmelanoma skin malignancies; 5) Serious concomitant comorbidities or contraindication to SBRT and/or ADT 6) Mental diseases that cannot ensure valid informed consent</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods of recruitment and random allocation</head><p>In phase 1 a hundred sixty consecutive patients will be enrolled at the Division of Radiation Oncology at the European Institute of Oncology (IEO), Milan, Italy within a multidisciplinary uro-oncology board. There will be a 1:1 randomization between Arm 1 and Arm 2. Patients will be stratified according to PSA doubling time (≤3 vs. &gt; 3 months) <ref type="bibr" target="#b15">[14,</ref><ref type="bibr">15]</ref>, initial localization of metastases (node vs bone) and diagnostic imaging (PET vs. MRI) [ <ref type="figure" target="#fig_0">Fig. 1]</ref>.</p><p>The patients will be randomized in either:</p><p>-ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously. -ARM 2: salvage SBRT (as described for ARM 1) + 6month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within 1 week before the start of SBRT.</p><p>Phase 2 is complementary to Phase 1. After SBRT completion, patients will be followed-up with PSA and testosterone measurements every 3 months and with clinical examination at 3 and 6 months and every 6 months thereafter. Questionnaires for the assessment of QoL will be administered within 2 weeks prior to randomization, at 3 and 12 months, and yearly thereafter.</p><p>Blood and plasma samples for biological evaluation and randomization of patients, at 3 months from completion of treatment and at clinical relapse. The samples will be stored in the "European Institute of Oncology Biobank".</p><p>Acute and late toxicity will be assessed according to the Common Toxicity Criteria for adverse events (CTCAE) toxicity criteria v4.3 <ref type="bibr" target="#b16">[16]</ref>, evaluated at 1 (acute toxicity) and at 3-6 months after the end SBRT and yearly afterwards (late toxicity). Time to castration-resistant disease will be assessed as time to start a systemic therapy (testosterone evaluation). A timeline of this study is summarized in <ref type="table" target="#tab_0">Table 1</ref>.</p><p>Moreover, a decision-tree algorithm, based on prognosis, imaging profile and biological phenotype will be developed: it will be addressed to identify recurrent PCa that remains oligometastatic and those that rapidly progress to a polymetastatic phase, thus allowing in the future to stratify patients who might avoid, or at least delay ADT, or not.</p><p>Data will be published at the end of the end of enrollment (2024).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment</head><p>Within 35 days prior to randomization, either a WB MRI or a Ch-PET/CT is mandatory to confirm a diagnosis of oligorecurrent disease, with a maximum of 3 pelvic/extrapelvic lymph nodes and/or bone metastases, and to exclude visceral disease.</p><p>According to SBRT technique, high doses will be delivered to small volumes in few fractions (≤5). In our framework, a schedule of 30 Gy in 3 fractions every other day (equivalent dose EQD2 = 98.6 Gy, considering α/β = 1.5 Gy), or equivalent regimens depending on disease site location will be used. Treatment planning and delivery will be performed using dedicated systems, such as Iplannet-Vero (Brainlab-Mitsubishi) and Multiplan-CyberKnife (Accuray), Eclipse-Trilogy (Varian) and Tomotherapy (Accuray). As far as image-guidance is concerned, Vero, Trilogy and Tomotherapy use a pre-treatment cone-beam CT whereas CyberKnife is based on intrafraction X-Rays.</p><p>Thus, CyberKnife needs fiducials or spine tracking. Cyber-Knife is preferred when particular attention to critical structures is required and spine tracking is possible. Strict quality assurance protocols will be implemented to ensure the accuracy in dose delivery.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endpoints of the study</head><p>The primary objective is to compare the progressionfree survival (PFS) defined as the absence of new metastatic lesions (local, regional or distant) between the two arms.  The secondary endpoints are as follows:</p><p>1) comparison of overall survival (OS) 2) biochemical progression-free survival (BPFS) 3) ADT-free survival 4) local control 5) treatment-induced acute and late toxicity 6) time to castration-resistant disease 7) QoL between the two arms 8) development of a dedicated biobanking (collection of plasma and serum) for further biological investigation of predictive/diagnostic factors for personalized treatment 9) the preliminary evaluation of prognostic biomarkers 10) the correlation between imaging-derived parameters and treatment outcome</p><p>The present research project will be developed for 60 months, during which specific milestones will be achieved and documented.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discontinuation of the treatment/ disease progression</head><p>In case of biochemical progression (defined according to the EAU guidelines <ref type="bibr" target="#b14">[13]</ref>) after SBRT, a new imaging scan should be considered: a WB MRI or Ch-PET/CT scan at time of biochemical progression or symptomatic progression and 6-montly afterwards until clinical progression will be performed. Further treatments (including ADT or other treatments according to the institutional policy) should not be started for biochemical progression without documented clinical progression on WB MRI or Ch-PET/CT. Repeated SBRT is allowed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical consideration and study registration</head><p>The study will be performed in accordance with the Declaration of Helsinki and will comply to the International Conference on Harmonization and Good Clinical Practice. All possible treatments and examinations for CRPC are undertaken after obtaining written informed consent from the patients before registration. This trial was supported by the research grants from the Italian Association for Cancer Research (AIRC) IG-22159.</p><p>The RADIOSA study was approved by the Ethics Committee of "IRCCS Istituto Europeo di Oncologia and Centro Cardiologico Monzino" (IEO-997).</p><p>The study has been registered at clinicaltrials.gov (NCT03940235).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Calculation of the target sample size</head><p>The main endpoint of this study is time to progression (local, biochemical and clinical progression) in oligometastatic PCA patients. We designed a randomized phase II selection study in which patients are randomized to two treatments and the results with the longest time to progression is selected for further study <ref type="bibr" target="#b13">[12]</ref>. The aim is to compare time to progression between the two study arms: SBRT only or SBRT and hormonotherapy, with α = 0.10 and β = 0.20. It is estimated that the median delay to start palliative ADT after metastasis-directed therapy is approximately 24 months <ref type="bibr" target="#b17">[17]</ref>. In order to detect a 12-month difference in the main endpoint from 12 to 24 months, a total of 152 patients will be needed, using a two-sided hypothesis based on the F distribution. Assuming a 5% rate of loss to follow-up, a total of 160 patients will be accrued over 36 months with 24 months of additional follow-up. We expect an accrual rate of 53 patients per year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Recently, the concept of ADT-free survival, intended as the time to the delayed start of ADT, in order to spare the related negative side effect, such as the increased occurrence of cardiovascular events and metabolic syndrome, that significantly affect the QoL <ref type="bibr" target="#b8">[7]</ref>. The aim of SBRT in this setting is to achieve local control and delay progression, and thereby postpone the need for further treatments.</p><p>From the clinical standpoint, the emergence of castration resistance is usually a nearby antecedent of widespread disease progression, visceral involvement and death from PCa. Therefore, preservation of the responsiveness to ADT is crucial in the long-term management of patients with metastatic PCa.</p><p>Also, from socio-economic point of view, 12 months without ADT can be considered a consistent gain for the National Health System, especially considering the relevant costs of the new and spreading anti-androgens like Abiraterone and Enzalutamide <ref type="bibr" target="#b6">[5]</ref>.</p><p>Current knowledge is mainly based on retrospective and non-randomized studies, thus suffering from heterogeneous population (i.e., due to biased patient selection) and inappropriate sample power <ref type="bibr" target="#b18">[18]</ref>.</p><p>It is evident that also in the setting of metastatic PCa, prostatic definitive radiotherapy could find a place. First data derived from retrospective trials by Löppenberg et al. and Rusthoven et al. demonstrated an improvement in OS for patients who underwent radiation therapy targeting the prostate in comparison to those who received only hormonal treatment <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref>.</p><p>The oligometastatic concept has been developed in the last years and recent trials show interesting results on adding local treatments (LCT) (such as radiotherapy or surgery) at standard therapy. Particularly, it is important to mention the results achieved by Gomez and Palma. Gomez et al., that conducted a randomized phase II trial on oligometastatic NSCLC, reporting a significant PFS benefit with LCT (both radiotherapy or surgery) vs maintenance systemic therapy (14.4 months vs 4.4 months respectively) <ref type="bibr" target="#b18">[18]</ref>. In another randomized phase II trial, named SABR-COMET, a benefit in OS in the SBRT arm for the oligometastatic setting compared to palliative treatment was demonstrated (41 months vs 28 months) <ref type="bibr" target="#b21">[21]</ref>.</p><p>The HORRAD study is a multi-centric prospective study, randomized controlled trial recruiting bone metastatic PCa patients. The objective was to compare irradiation of primary prostatic tumor with external beam radiation therapy with ADT versus ADT only. The trial revealed no significant difference in OS. However, subgroup analysis suggests that radiotherapy to the prostate actually improves OS in patients with a low metastatic burden (&lt; 5 bone lesions) <ref type="bibr" target="#b22">[22]</ref>.</p><p>More recently, subgroup analysis of patients with a low metastatic burden from STAMPEDE (a phase 3 randomized controlled trial) showed that OS was improved with radiotherapy, giving a three-year survival of 81% in these men, compared to 73% in the standard treatment group <ref type="bibr" target="#b6">[5]</ref>.</p><p>For Murphy et al., the approach to metastatic PCa "catching 'em all", or "pokemet", must be considered experimental <ref type="bibr" target="#b23">[23]</ref>. Also, in this setting, data from retrospective studies suggest that cancer specific and OS is improved with Metastasis-directed therapy (MDT) compared to the standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes <ref type="bibr" target="#b4">[3]</ref>. Among prospective studies, STOMP and ORIOLE trials are worth mentioning <ref type="bibr" target="#b24">[24,</ref><ref type="bibr" target="#b25">25]</ref>.</p><p>However, despite encouraging data, some authors remain skeptical that MDT will delay the use of ADT. Moreover, this argument is a weak endpoint compared to PFS or OS especially given that timing for using hormonotherapy remains controversial.</p><p>Whereas the use of systemic therapy was largely investigated by several large clinical trials, currently, limited studies focus on metastasis-directed SBRT. These studies, despite short follow-up that limited the evaluation of OS and cancer-specific survival, showed that metastasisdirected SBRT is a safe treatment, reaching a high local control (about 95%) with low-grade toxicity, generally limited to gastro-intestinal effects <ref type="bibr" target="#b4">[3,</ref><ref type="bibr" target="#b26">[26]</ref><ref type="bibr" target="#b27">[27]</ref><ref type="bibr" target="#b28">[28]</ref><ref type="bibr" target="#b29">[29]</ref>.</p><p>So, new biomarkers are mandatory to help determining the natural history of the disease and to select the patients who could actually benefit from MDT. The discovery of miRNA seems to give a start of answers to many questions that arise.</p><p>Recent studies have demonstrated that miRNAs influence many stages of carcinogenesis and can effectively modulate tumor radiosensitivity at different levels, by affecting targets involved in DNA damage repair, cell cycle checkpoint, apoptosis, signal transduction pathways and tumor microenvironment. Thus, the identification of miRNA involved in DNA damage radiation response is not excluded and might lead to the use of Poly (ADP-ribose) polymerase (PARP) inhibitors in the near future <ref type="bibr" target="#b26">[26]</ref>.</p><p>In a recent published study by Pitroda PS et al., a molecular basis (such as mi-RNA profiling) for oligometastatic state in colorectal liver metastasis was identified in order to predict clinical outcome and establish clinical risk factors associated with long-term survival following hepatic resection <ref type="bibr" target="#b30">[30]</ref>.</p><p>According to Formosa et al. a series of miRNAs called oligomers would be typical of oligometastatic diseases, and thus have a role in the developmentof the oligometastatic state and the transition from an oligometastatic state to a polymetastatic disease <ref type="bibr" target="#b31">[31]</ref>.</p><p>Overall, data and tools to guide an optimal therapeutic choice in this setting are not validated and the standard of care to recurrent PCa remains ADT, with significant side effects and deterioration of QoL <ref type="bibr" target="#b11">[10]</ref>. To address a larger consensus on oligorecurrent PCa management, randomized clinical trials selecting homogeneous patient population are needed. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc>Study design</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Abbreviations</head><label></label><figDesc>ADT: Androgen deprivation therapy; AIRC: Italian Association for Cancer Research; BPFS: Biochemical progression-free survival; Ch-PET/CT: Choline positron emission tomography/computed tomography; CTCAE: Common Toxicity Criteria for adverse events; EAU: Association of Urology; ECOG: Eastern Cooperative Oncology Group; IEO: European Institute of Oncology; LCT: Local treatments; LHRH: Luteinizing hormone-releasing hormone; MDT: Metastasis-directed therapy; MET-RADS: METastasis Reporting and Data System; OCS-PCa: Oligorecurrent-castration-sensitive PCa; OS: Overall survival; PARP: Poly (ADP-ribose) polymerase inhibitors; pCa: Prostate Cancer; PFS: Progression-free survival; PSA: Prostate-specific antigen; PSMA PET: Prostate-Specific Membrane Antigen Positron Emission Tomography; QoL: Quality of Life; SBRT: Stereotactic body radiotherapy; WB MRI: Whole-Body Magnetic Resonance Imaging</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Timeline of the study</figDesc><table><row><cell></cell><cell>Screening 2 weeks within</cell><cell>1 months after</cell><cell>3 months after</cell><cell>Every 3</cell><cell>12 months</cell><cell>Every</cell><cell>Biochimical</cell><cell>Clinical</cell></row><row><cell></cell><cell>randomization</cell><cell>end of RT</cell><cell>end of RT</cell><cell>months</cell><cell>after end of RT</cell><cell>year</cell><cell>relapse</cell><cell>relapse</cell></row><row><cell>Physical examination</cell><cell>x</cell><cell></cell><cell>x</cell><cell></cell><cell>x</cell><cell></cell><cell></cell></row><row><cell>PSA/testosterone</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell><cell>x</cell><cell></cell><cell></cell></row><row><cell>GS</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Previous treatments for PCa x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ECOG score</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Comorbidities</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Imaging</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Blood tests (NLR)</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Serum and plasma</cell><cell>x</cell><cell></cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>x</cell></row><row><cell>collection</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Acute toxicity assessment</cell><cell></cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Late toxicity assessment</cell><cell></cell><cell></cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>QoL</cell><cell>x</cell><cell></cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell><cell></cell><cell>x</cell></row><row><cell>Cho-PET/TC or RM-WB</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>x</cell><cell>x</cell></row></table><note></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>The authors would like to thank the Associazione Italiana per la Ricerca sul Cancro (AIRC), who supported the study. The Sponsor did not play any role in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript, nor in the decision to submit the manuscript for publication.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Authors' contributions GM <ref type="bibr" target="#b0">1</ref> , DC and BAJF were responsible for the study conception and design, and had final responsibility for the decision to submit the manuscript for publication. GM 1 , GC, DZ, DPR and MA drafted the manuscript. SG, CF, FAM, SA, GP, MA <ref type="bibr" target="#b9">8</ref> were responsible for acquisition and analysis of data. GM 7 , KM, GB and SP were responsible for interpretation of data. FC, GP <ref type="bibr">2,</ref><ref type="bibr" target="#b7">6</ref> , ODC, PPDF, GV and RO substantially revised the work. All authors have read and approved the final version of the manuscript and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>This study is funded by AIRC. All other processes including the study design, collection of data, analyses, interpretations, and the writing of the manuscript were the responsibilities of Division of Radiotherapy IEO. This trial was supported by the research grant from the Italian Association for Cancer Research (AIRC) IG-22159.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p>Data of this article will be not available until the final report of this study to avoid bias toward the analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p>The RADIOSA study was approved by the Ethics Committee of "IRCCS Istituto Europeo di Oncologia and Centro Cardiologico Monzino" (IEO-997). All participants will sign an Informed Consent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p>The authors declare that they have no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author details</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Compare SBRT +/− ADT for oligorecurrent-castration-sensitive PCa (OCS-PCa) in terms of efficacy, toxicity and Quality of Life (QoL)</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Develop biology/imaging based prognostic tool that allows identifying OCS-PCa subclasses</title>
		<imprint/>
	</monogr>
	<note>Methods: This is a randomized phase II clinical trial, recruiting 160 OCS-PCa in 3 years. with progression-free survival</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Soerjomataram</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Dikshit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="359" to="86" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Oligometastases revisited</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Weichselbaum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Hellman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="378" to="82" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Radiotherapy as metastasis directed therapy for oligometastatic prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">De</forename><surname>Bleser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">T</forename><surname>Ost</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Urol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="587" to="95" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Impact of the site of metastases on survival in patients with metastatic prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gandaglia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">I</forename><surname>Karakiewicz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Briganti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="325" to="359" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Brawley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">392</biblScope>
			<biblScope unit="page" from="2353" to="66" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gravis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Boher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2018.02.001</idno>
		<ptr target="https://doi.org/10.1016/j.eururo.2018.02.001" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="847" to="55" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Stereotactic body radiotherapy for oligometastases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Tree</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">S</forename><surname>Khoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Eeles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="28" to="37" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Inter-and intra-observer repeatability of quantitative whole-body, diffusion-Weightedv imaging (WBDWI) in metastatic bone disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Blackledge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Tunariu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Orton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">153840</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Prognostic significance of neutrophil-tolymphocyte ratio in prostate cancer: evidence from 16,266 patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">22089</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">METastasis reporting and data system for prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imagingbased evaluations of multiorgan involvement in advanced prostate Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Padhani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">E</forename><surname>Lecouvet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Tunariu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="81" to="92" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Quality of life three years after diagnosis of localised prostate cancer: population based cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">P</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">T</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Egger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page">4817</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Design issues of randomized phase II trials and a proposal for phase II screening trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">V</forename><surname>Rubinstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Korn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Freidlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="7199" to="206" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castrationresistant prostate Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Cornford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Bolla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="630" to="672" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">PSA velocity and doubling time in diagnosis and prognosis of prostate Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Vickers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Brewster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Med Surg Urol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="162" to="170" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Common Terminology Criteria for Adverse Events v4.3. National Cancer Institute</title>
		<ptr target="https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm" />
		<imprint>
			<date type="published" when="2019-05" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Jilg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Rischke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Reske</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Urol</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="2190" to="2197" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Local consolidative therapy vs. maintenance therapy or observation for patients with Oligometastatic nonsmall-cell lung Cancer: long-term results of a multi-institutional, phase II, randomized study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">R</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1558" to="65" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">G</forename><surname>Rusthoven</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">W</forename><surname>Flaig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="2835" to="2877" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Löppenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Dalela</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Karabon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="14" to="23" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Palma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Harrow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">393</biblScope>
			<biblScope unit="page" from="2051" to="2059" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lms</forename><surname>Boevé</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mccm</forename><surname>Hulshof</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">N</forename><surname>Vis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="410" to="418" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Whole body irradiation; radiobiology or medicine?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Mole</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Radiol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="234" to="4124" />
			<date type="published" when="1953" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ost</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Reynders</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Decaestecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="446" to="53" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate CancEr (ORIOLE)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Radwan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Pillips</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ross</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">453</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Berkovic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">De</forename><surname>Meerleer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Delrue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Genitourin Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="27" to="32" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">M</forename><surname>Barney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Oncol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">215</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Schick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Jorcano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Nouet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1622" to="1630" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Muacevic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kufeld</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Rist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="455" to="60" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Integrated molecular subtuping defines a curable olimetastatic state in colorectal liver metastasis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Pitroda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">N</forename><surname>Khodarev</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">1793</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in meta-static prostate cancer cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Formosa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">K</forename><surname>Markert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Lena</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="5173" to="82" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
